Trial · NCT07906496
Acceptance and Committment Therapy Combined With Ketamine in Difficult-to-Treat Depression.
NCT07906496, Not applicable, Not yet recruiting, University of British Columbia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acceptance and Committment Therapy Combined With Ketamine in Difficult-to-Treat Depression. Trials, record NCT07906496. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906496
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Acceptance and Committment Therapy Combined With Ketamine in Difficult-to-Treat Depression.
- NCT number
- NCT07906496
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 50 participants, estimated
- Lead sponsor
- University of British Columbia
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- K-ACT Intervention
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feasibility outcomes | 18 months/end of study | Rate of recruitment/total participants enrolled, treatment attendance (sessions attended), retention, and follow-up completion |
| Primary | Safety outcomes | 18 months/end of study | Participant safety will be monitored through routine clinical assessments, including ongoing evaluation of suicidality and adverse events. |
| Secondary | Change in Work and Social Adjustment Scale (WSAS) | Changes from baseline to 3-month follow-up (3 months post completion of acute/index ketamine treatments) | The Work and Social Adjustment Scale (WSAS) is a measure of functioning. It is a short 5-items self-reported scale. Each item is scored 0 to 8. The higher the score, the greater the functional impairment. |
| Secondary | Change in Questionnaire about the Process of Recovery (QPR-15) | Changes from baseline to 3-month follow-up (3 months post completion of acute/index ketamine treatments). | The Questionnaire about the Process of Recovery (QPR-15) is a self-reported scale on personal recovery. There are 15 items rated on a scale from 0 to 4 (0= disagree strongly, 1=disagree, 2=neither agree nor disagree, 3=agree, 4=agree strongly). Higher scores indicate greater recovery. |
| Secondary | Change in the Montgomery-Åsberg Depression Rating Scale (MADRS) | Changes from baseline to 3-month follow-up (3 months post completion of acute/index ketamine treatments) | The Montgomery-Åsberg Depression Rating Scale is a 10-item, clinician-rated scale to rate the severity of depression. Items are scored from 0 to 6. The total possible score is 60. Higher scores indicate greater depression severity. |
| Secondary | Change in Acceptance and Commitment Questionnaire (AAQ-II) | Changes from baseline to 3-month follow-up (3 months post completion of acute/index ketamine treatments) | The Acceptance and Commitment Questionnaire (AAQ-II) is a measure of psychological flexibility. It is a self-reported scale with 7 items, each scored on a 7-points scale. Higher values indicate less flexibility, while lower scores more flexibility. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906496
GET https://conductscience.org/api/trials/v1/NCT07906496/registered